文献速递妇科

晚期低级别浆液性卵巢癌患者初次肿瘤细胞减灭术联合辅助激素单药治疗:在不影响生存的前提下减少过度治疗?

Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
PubMed 文献 · Gynecol Oncol · 2017-07-30

在两家学术癌症中心开展的回顾性研究纳入27例II-IV期低级别浆液性卵巢癌患者,26例接受初次肿瘤细胞减灭术、1例接受新辅助化疗后手术,术后均接受激素单药治疗;中位随访41个月,仅6例(22.2%)复发、2例死于疾病,2年无进展生存率和总生存率分别为82.8%和96.3%。作者认为手术仍是主要治疗手段,接受辅助激素治疗的晚期患者可能不需要化疗,并计划开展III期试验。

要点

  • 27例II-IV期低级别浆液性卵巢癌中,26例接受初次肿瘤细胞减灭术、1例接受新辅助化疗后手术,术后均接受激素单药治疗。
  • 中位随访41个月,6例(22.2%)复发、2例死于疾病,2年无进展生存率82.8%、总生存率96.3%。
  • 96%肿瘤表达雌激素受体、32%表达孕激素受体;术后来曲唑占55.5%、阿那曲唑占37.1%、他莫昔芬占7.4%。

核心结论

  • 作者认为手术仍是主要治疗手段,接受辅助激素治疗的晚期低级别浆液性卵巢癌患者可能不需要化疗。
  • 作者计划开展合作组III期试验以确定该卵巢癌亚型的最佳治疗。

研究设计与样本

  • 在两家学术癌症中心开展的回顾性研究,纳入2004年至2016年间接受初次或中间型肿瘤细胞减灭术、术后辅助激素治疗的II-IV期低级别浆液性卵巢癌患者。
  • 共27例患者,妇科病理学家复核所有病例;计算2年无进展生存率和总生存率。

主要发现

  • 27例中26例接受初次肿瘤细胞减灭术联合激素治疗,1例接受新辅助化疗后肿瘤细胞减灭术联合激素治疗;中位年龄47.5岁。
  • 分期为II期2例、IIIA期6例、IIIC期18例、IV期1例;85.2%达到无肉眼残留的最佳肿瘤细胞减灭。
  • 96%肿瘤表达雌激素受体,仅32%表达孕激素受体;术后来曲唑占55.5%、阿那曲唑占37.1%、他莫昔芬占7.4%。
  • 中位随访41个月,仅6例(22.2%)出现肿瘤复发,2例死于疾病;中位无进展生存期和总生存期尚未达到。
  • 2年无进展生存率82.8%、总生存率96.3%;3年无进展生存率79.0%、总生存率92.6%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Women with advanced-stage, low-grade serous ovarian carcinoma (LGSC) have low chemotherapy response rates and poor overall survival. Most LGSC tumors overexpress hormone receptors, which represent a potential treatment target. Our study objective was to determine the outcomes of patients with advanced-stage LGSC treated with primary cytoreductive surgery (CRS) and hormone therapy (HT). METHODS: A retrospective study was performed at two academic cancer centers. Patients with Stage II-IV LGSC underwent either primary or interval CRS followed by adjuvant HT between 2004 and 2016. Gynecologic pathologists reviewed all cases. Two-year progression-free (PFS) and overall survival (OS) were calculated. RESULTS: Twenty-seven patients were studied; primary CRS followed by HT were administered in 26, while 1 patient had neoadjuvant chemotherapy followed by CRS and HT. The median patient age was 47.5, and patients had Stage II (n=2), Stage IIIA (n=6), Stage IIIC (n=18), and Stage IV (n=1) disease. Optimal cytoreduction to no gross residual was achieved in 85.2%. Ninety six percent of tumors expressed estrogen receptors, while only 32% expressed progesterone receptors. Letrozole was administered post operatively in 55.5% cases, anastrozole in 37.1% and tamoxifen in 7.4%. After a median follow up of 41months, only 6 patients (22.2%) have developed a tumor recurrence and two patients have died of disease. Median PFS and OS have not yet been reached, but 2-year PFS and OS were 82.8% and 96.3%, respectively, and 3-year PFS and OS were 79.0% and 92.6%, respectively. CONCLUSIONS: Our series describes the initial experience with cytoreductive surgery and hormonal monotherapy for women with Stage II-IV primary ovarian LGSC. While surgery remains the mainstay of treatment, chemotherapy may not be necessary in patients with advanced-stage disease who receive adjuvant hormonal therapy. A cooperative group, Phase III trial is planned to define the optimal therapy for women with this ovarian carcinoma subtype.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Fader AN, Bergstrom J, Jernigan A, et al. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol. 2017. PMID: 28768570. doi:10.1016/j.ygyno.2017.07.127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。